A new study has identified Toll-Like Receptor 2 (TLR2) as a major driver of immune resistance in pancreatic ductal adenocarcinoma (PDAC), one of the deadliest forms of cancer. Researchers found that TLR2 prevents cancer-fighting T cells from entering tumors, helping explain why pancreatic cancer often resists immunotherapy.
Using mouse models and human tumor data, scientists showed that CAR T-cell therapy worked well in “hot” tumors already containing T cells, but failed in “cold” tumors where T cells were blocked from entering. Elevated TLR2 signaling was linked to this immune exclusion.
When researchers genetically removed TLR2 or treated tumors with anti-TLR2 therapies, tumors grew more slowly, T-cell infiltration increased, and survival improved. Antibody treatments targeting TLR2 also showed strong anti-tumor effects in resistant pancreatic cancer models.
The findings suggest TLR2 could become a promising new immunotherapy target for pancreatic cancer.